Fig. 1From: 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profilingTreatment scheme of the SAKK 19/05 trial. Patients received BE until progression or unacceptable toxicity. Upon disease progression, patients received standard chemotherapy with cisplatin and gemcitabineBack to article page